News

Stay informed about our scientific advances, clinical progress, and company updates.

Press Release
November 12, 2026

Apmonia Therapeutics announces first patient treated in Phase 1/2a study of TAX2, a new approach to cancer immunotherapy

Read more
Apmonia Therapeutics press release of 12 November 2026: first patient treated in the Phase 1/2a study of TAX2

No results